Deutsche Bank Upgrades DaVita Stock to Buy Amid Rising Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: CNBC
- Upgraded Outlook: Deutsche Bank upgraded DaVita's rating from hold to buy and raised its price target from $126 to $220, indicating a 40% upside from Tuesday's close, reflecting strong confidence in the company's future performance.
- Earnings Beat: DaVita reported first-quarter earnings with revenue per treatment at $417.59, exceeding market expectations by $8.30 and marking a 4.4% year-over-year increase, indicating enhanced competitiveness in the treatment services sector.
- Growth Highlights: Analysts noted that the two shining stars of the quarter were revenue per treatment and treatment growth, with treatment numbers coming in 10 basis points above analysts' consensus, suggesting a rebound in market demand that could drive future performance.
- Positive Market Reaction: Following the earnings report, DaVita's shares rose nearly 6% in after-hours trading, and the stock has gained 38% year-to-date, reflecting investor optimism about the company's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 154.080
Low
144.00
Averages
162.50
High
190.00
Current: 154.080
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAVITA, INC.: DEUTSCHE BANK UPGRADES RATING TO BUY FROM HOLD
Company Announcement: Davita, Inc. has announced that Deutsche Bank will raise funds to facilitate a purchase from Hold.
Financial Strategy: The move indicates a strategic financial maneuver by Davita, Inc. to enhance its market position through acquisitions.
See More
DAVITA, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $126 TO $220
Deutsche Bank's Target Price Increase: Deutsche Bank has raised its target price for Davita, Inc. from $126 to $220.
Implications of the Price Adjustment: This significant increase suggests a positive outlook on Davita's performance and potential growth in the market.
See More
Significant Stock Movements for AMD and Others
- AMD Strong Guidance: AMD shares surged 20% after issuing a second-quarter revenue forecast of $11.2 billion, exceeding the analyst estimate of $10.52 billion, with first-quarter results also surpassing expectations, indicating robust performance in the semiconductor market.
- Super Micro Earnings Beat: Super Micro's stock jumped nearly 15% as fourth-quarter profit expectations range from 65 to 79 cents per share, significantly above Wall Street's call for 55 cents, with third-quarter adjusted earnings of 84 cents per share showcasing its competitiveness in the server market.
- CVS Health Performance Boost: CVS Health shares gained 4% after reporting first-quarter adjusted earnings of $2.57 per share and revenue of $100.43 billion, both exceeding analyst expectations, while the company raised its full-year earnings outlook, reflecting strong performance in the pharmacy benefits sector.
- Lucid Group Worsening Losses: Lucid Group shares fell 3% as the company reported a first-quarter loss of $3.46 per share, significantly worse than the expected loss of $2.64, with revenue of $282.5 million missing the $440.4 million target, highlighting challenges in the electric vehicle market.
See More
Deutsche Bank Upgrades DaVita Stock to Buy Amid Rising Demand
- Upgraded Outlook: Deutsche Bank upgraded DaVita's rating from hold to buy and raised its price target from $126 to $220, indicating a 40% upside from Tuesday's close, reflecting strong confidence in the company's future performance.
- Earnings Beat: DaVita reported first-quarter earnings with revenue per treatment at $417.59, exceeding market expectations by $8.30 and marking a 4.4% year-over-year increase, indicating enhanced competitiveness in the treatment services sector.
- Growth Highlights: Analysts noted that the two shining stars of the quarter were revenue per treatment and treatment growth, with treatment numbers coming in 10 basis points above analysts' consensus, suggesting a rebound in market demand that could drive future performance.
- Positive Market Reaction: Following the earnings report, DaVita's shares rose nearly 6% in after-hours trading, and the stock has gained 38% year-to-date, reflecting investor optimism about the company's prospects.
See More
DaVita Exceeds Q1 2026 Earnings Expectations
- Financial Performance Surpasses Expectations: DaVita reported an adjusted operating income of $482 million for Q1, exceeding forecasts by approximately $50 million, demonstrating balanced outperformance across treatment volume, revenue per treatment, and cost management, which enhances market confidence.
- Guidance Raised for the Year: The management has raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, primarily driven by higher treatment volume expectations and lower patient care costs, reflecting confidence in future growth.
- Ongoing Technology Investment: The introduction of the new tool, 'ScheduleHub', which dynamically processes patient and teammate availability to optimize scheduling in real-time, indicates the company's continued investment in AI and technological infrastructure aimed at improving operational efficiency.
- Cautious on ACA Impact: While the ACA open enrollment is trending slightly favorable, management warned that an increase in patients selecting lower-tier bronze plans could lead to a modest decline in revenue per treatment, highlighting uncertainties regarding future income.
See More
AMD's Strong Guidance Boosts Stock Price
- AMD Earnings Beat: AMD's strong second-quarter revenue guidance of $11.2 billion, with a $300 million variance, surpasses analyst expectations of $10.52 billion, indicating robust demand and growth potential in the semiconductor market.
- Super Micro Profit Expectations: Super Micro Computer's stock surged 19% as fourth-quarter profit expectations range from 65 to 79 cents per share, significantly exceeding Wall Street's forecast of 55 cents, with third-quarter adjusted earnings of 84 cents showcasing its competitive edge in the server market.
- Jacobs Solutions Guidance Raised: Jacobs Solutions' shares fell 2% despite beating second-quarter adjusted earnings and revenue expectations, as the company raised its full-year earnings guidance to between $7.10 and $7.35 per share, reflecting business resilience.
- Lucid Group Misses Estimates: Lucid Group's stock dropped 2% after reporting a first-quarter loss of $3.46 per share, significantly worse than the expected $2.64 loss, with revenue of $282.5 million falling short of the $440.4 million forecast, highlighting challenges in the electric vehicle market.
See More
DAVITA, INC.: DEUTSCHE BANK UPGRADES RATING TO BUY FROM HOLD
Company Announcement: Davita, Inc. has announced that Deutsche Bank will raise funds to facilitate a purchase from Hold.
Financial Strategy: The move indicates a strategic financial maneuver by Davita, Inc. to enhance its market position through acquisitions.
See More
DAVITA, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $126 TO $220
Deutsche Bank's Target Price Increase: Deutsche Bank has raised its target price for Davita, Inc. from $126 to $220.
Implications of the Price Adjustment: This significant increase suggests a positive outlook on Davita's performance and potential growth in the market.
See More
Significant Stock Movements for AMD and Others
- AMD Strong Guidance: AMD shares surged 20% after issuing a second-quarter revenue forecast of $11.2 billion, exceeding the analyst estimate of $10.52 billion, with first-quarter results also surpassing expectations, indicating robust performance in the semiconductor market.
- Super Micro Earnings Beat: Super Micro's stock jumped nearly 15% as fourth-quarter profit expectations range from 65 to 79 cents per share, significantly above Wall Street's call for 55 cents, with third-quarter adjusted earnings of 84 cents per share showcasing its competitiveness in the server market.
- CVS Health Performance Boost: CVS Health shares gained 4% after reporting first-quarter adjusted earnings of $2.57 per share and revenue of $100.43 billion, both exceeding analyst expectations, while the company raised its full-year earnings outlook, reflecting strong performance in the pharmacy benefits sector.
- Lucid Group Worsening Losses: Lucid Group shares fell 3% as the company reported a first-quarter loss of $3.46 per share, significantly worse than the expected loss of $2.64, with revenue of $282.5 million missing the $440.4 million target, highlighting challenges in the electric vehicle market.
See More
Deutsche Bank Upgrades DaVita Stock to Buy Amid Rising Demand
- Upgraded Outlook: Deutsche Bank upgraded DaVita's rating from hold to buy and raised its price target from $126 to $220, indicating a 40% upside from Tuesday's close, reflecting strong confidence in the company's future performance.
- Earnings Beat: DaVita reported first-quarter earnings with revenue per treatment at $417.59, exceeding market expectations by $8.30 and marking a 4.4% year-over-year increase, indicating enhanced competitiveness in the treatment services sector.
- Growth Highlights: Analysts noted that the two shining stars of the quarter were revenue per treatment and treatment growth, with treatment numbers coming in 10 basis points above analysts' consensus, suggesting a rebound in market demand that could drive future performance.
- Positive Market Reaction: Following the earnings report, DaVita's shares rose nearly 6% in after-hours trading, and the stock has gained 38% year-to-date, reflecting investor optimism about the company's prospects.
See More
DaVita Exceeds Q1 2026 Earnings Expectations
- Financial Performance Surpasses Expectations: DaVita reported an adjusted operating income of $482 million for Q1, exceeding forecasts by approximately $50 million, demonstrating balanced outperformance across treatment volume, revenue per treatment, and cost management, which enhances market confidence.
- Guidance Raised for the Year: The management has raised its 2026 adjusted operating income guidance to a range of $2.15 billion to $2.25 billion, primarily driven by higher treatment volume expectations and lower patient care costs, reflecting confidence in future growth.
- Ongoing Technology Investment: The introduction of the new tool, 'ScheduleHub', which dynamically processes patient and teammate availability to optimize scheduling in real-time, indicates the company's continued investment in AI and technological infrastructure aimed at improving operational efficiency.
- Cautious on ACA Impact: While the ACA open enrollment is trending slightly favorable, management warned that an increase in patients selecting lower-tier bronze plans could lead to a modest decline in revenue per treatment, highlighting uncertainties regarding future income.
See More
AMD's Strong Guidance Boosts Stock Price
- AMD Earnings Beat: AMD's strong second-quarter revenue guidance of $11.2 billion, with a $300 million variance, surpasses analyst expectations of $10.52 billion, indicating robust demand and growth potential in the semiconductor market.
- Super Micro Profit Expectations: Super Micro Computer's stock surged 19% as fourth-quarter profit expectations range from 65 to 79 cents per share, significantly exceeding Wall Street's forecast of 55 cents, with third-quarter adjusted earnings of 84 cents showcasing its competitive edge in the server market.
- Jacobs Solutions Guidance Raised: Jacobs Solutions' shares fell 2% despite beating second-quarter adjusted earnings and revenue expectations, as the company raised its full-year earnings guidance to between $7.10 and $7.35 per share, reflecting business resilience.
- Lucid Group Misses Estimates: Lucid Group's stock dropped 2% after reporting a first-quarter loss of $3.46 per share, significantly worse than the expected $2.64 loss, with revenue of $282.5 million falling short of the $440.4 million forecast, highlighting challenges in the electric vehicle market.
See More
